No benefits seen in terms of weight loss, diabetes remission, surgery safety<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
WEDNESDAY, March 12, 2025 (HealthDay News) — Neoadjuvant semaglutide before metabolic and bariatric surgery (MBS) is not beneficial in terms of weight loss, according to a research letter published online March 5 in JAMA Surgery<\/em>.<\/p>\n Vasundhara Mathur, M.D., from Brigham and Women’s Hospital in Boston, and colleagues conducted a retrospective cohort study to examine the long-term outcomes of neoadjuvant semaglutide before MBS. Patients who received semaglutide before MBS from 2017 to 2024 were matched 1:1 with patients who did not receive semaglutide before MBS using nearest-neighbor propensity score matching (182 patients and 182 controls).<\/p>\n The researchers found that at postoperative months 6, 9, and 12, total weight loss (TWL) was lower for patients who received preoperative semaglutide than controls (median 12-month TWL: 21.0 versus 26.0 percent). For patients who received semaglutide, combined multimodality TWL was higher at postoperative month 3 but did not differ thereafter. Patients receiving preoperative semaglutide versus controls had similar median hemoglobin A1c levels before MBS and one year after MBS. Furthermore, both cohorts had a similar number of patients with diabetes remission at postoperative year 1. Early major postoperative complications did not differ significantly across cohorts.<\/p>\n “This study showed neoadjuvant semaglutide did not confer benefits for weight loss, diabetes remission, or MBS safety,” the authors write.<\/p>\n Several authors disclosed ties to the biopharmaceutical industry; one author has three patents pending.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n